Business · 20/05/1999Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for Omnicef Oral Suspension Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of Omnicef Oral Suspension, a human drug product, following a submission to the Commissioner of Patents and Trademarks.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →